Study of Fatal Car Accidents Suggests Medical Marijuana May Be Helping Curb Opioid Use

Researchers analyzed 1999-2013 Fatality Analysis Reporting System data from 18 U.S. states that tested for alcohol and other drugs in at least 80 percent of drivers who died within one hour of crashing. They looked at opioid positivity among drivers ages 21 to 40 who crashed their cars in states with an operational medical marijuana law compared with drivers crashing in states before those laws went into effect. There was an overall reduction in opioid positivity for most states after implementation of an operational medical marijuana law.

“We would expect the adverse consequences of opioid use to decrease over time in states where medical marijuana use is legal, as individuals substitute marijuana for opioids in the treatment of severe or chronic pain,” explained June H. Kim, MPhil, a doctoral student in the Department of Epidemiology at the Mailman School of Public Health, and lead author.

Among the 68,394 deceased drivers, approximately 42 percent were fatally injured in states that had an operational medical marijuana laws, 25 percent died in states before an operational law went into effect, and 33 percent died in states that had never passed a medical marijuana law. In 1996, California was the first state to pass a voter-initiated medical marijuana law. Since then, 22 additional states and the District of Columbia have enacted their own medical marijuana laws either by voter initiatives or through state legislation.“The trend may have been particularly strong among the age group surveyed because minimum age requirements restrict access to medical marijuana to patients age 21 and older, and most medical marijuana patients are younger than 45,” noted Kim. According to the authors, they would expect to see similar reductions in opioid use among older cohorts if medical marijuana is increasingly embraced by older generations. “This study is about the possible substitution relationship between marijuana and opioids. The toxicological testing data for fatally injured drivers lend some suggestive evidence that supports the substitution hypothesis in young adults, but not in older adults,”said Guohua Li, MD, DrPH, Mailman School professor of Epidemiology, the founding director of the Center for Injury Epidemiology and Prevention at Columbia, and senior author. “As states with these laws move toward legalizing marijuana more broadly for recreational purposes, future studies are needed to assess the impact these laws may have on opioid use,” noted Kim.

Co-authors are: Julian Santaella-Tenorio, Katherine M. Keyes, Deborah Hasin, and Silvia S. Martins with the Department of Epidemiology, Mailman School of Public Health; Christine Mauro and Julia Wrobel with the Department of Biostatistics, Mailman School of Public Health; and Magdalena Cerda` with the Department of Emergency Medicine, University of California, Davis.

The study was supported by the National Institute on Drug Abuse grants T32DA031099-01A1, R01DA037866-01, R01DA034244, R49CE002096, and R21DA029670. Columbia University’s Mailman School of Public HealthFounded in 1922, Columbia University’s Mailman School of Public Health pursues an agenda of research, education, and service to address the critical and complex public health issues affecting New Yorkers, the nation and the world. The Mailman School is the third largest recipient of NIH grants among schools of public health. Its over 450 multi-disciplinary faculty members work in more than 100 countries around the world, addressing such issues as preventing infectious and chronic diseases, environmental health, maternal and child health, health policy, climate change & health, and public health preparedness. It is a leader in public health education with over 1,300 graduate students from more than 40 nations pursuing a variety of master’s and doctoral degree programs. The Mailman School is also home to numerous world-renowned research centers including ICAP (formerly the International Center for AIDS Care and Treatment Programs) and the Center for Infection and Immunity. For more information, please visit www.mailman.columbia.edu.

Contact: Stephanie Berger at Columbia University's Mailman School of Public [email protected]